<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Accelerated phase chronic myeloid leukemia: Diagnosis and treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Accelerated phase chronic myeloid leukemia: Diagnosis and treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Accelerated phase chronic myeloid leukemia: Diagnosis and treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Negrin, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles A Schiffer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ehab Atallah, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 31, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm associated with t(9;22)(q34;q11), the so-called Philadelphia chromosome. This chromosomal rearrangement creates the
         <em>
          BCR-ABL1
         </em>
         fusion gene, which encodes BCR-ABL1, a constitutively active tyrosine kinase. Up to 90 percent of patients with CML present with chronic phase (CP) CML, which is a relatively indolent disorder that responds well to treatment with a BCR-ABL1 tyrosine kinase inhibitor (TKI). The remainder of patients present with advanced CML: either accelerated phase (AP) CML or blast phase (BP; also called blast crisis) CML.
        </p>
        <p>
         AP CML is distinguished from CP CML and BP CML according to myeloblast count, percentage of basophils, additional chromosomal abnormalities, and other clinico-pathologic features. Some patients initially present with AP CML (de novo AP CML), while others have disease that initially presented as CP CML, but transformed (ie, progressed) to AP while receiving treatment with a TKI. The distinction between de novo AP CML and transformed AP CML affects treatment decisions and prognosis.
        </p>
        <p>
         This topic discusses the diagnosis and management of AP CML.
        </p>
        <p>
         Treatment of CP CML, blast crisis CML, and use of hematopoietic cell transplantation (HCT) for CML are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4496.html" rel="external">
          "Overview of the treatment of chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4512.html" rel="external">
          "Treatment of chronic myeloid leukemia in blast crisis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4494.html" rel="external">
          "Hematopoietic cell transplantation in chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H567459261">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pretreatment evaluation of a patient with CML should include history and physical examination, performance status  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 1
         </a>
         ), and laboratory and clinical studies that enable accelerated phase (AP) CML to be distinguished from chronic phase (CP) CML and blast phase (BP) CML and establish baseline molecular studies for monitoring response to treatment.
        </p>
        <p>
         Patients with transformed AP CML (ie, AP CML that arose while undergoing treatment for CP CML) must also have molecular analysis for
         <em>
          BCR-ABL1
         </em>
         mutations. (See
         <a class="local">
          'Mutation testing'
         </a>
         below.)
        </p>
        <p>
         Initial evaluation, diagnosis, and differential diagnosis of CML are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H371661530">
         <span class="h2">
          Clinical and laboratory
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History
         </strong>
         should document:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         B symptoms (ie, unexplained fevers, drenching sweats, weight loss), anorexia, abdominal pain/fullness, bone pain
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Comorbid conditions (eg, cardiac dysrhythmias, heart failure, pancreatitis, liver disease, diabetes mellitus)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adherence to and tolerance for BCR-ABL1 tyrosine kinase inhibitor (TKI), if used previously
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         should note splenomegaly, hepatomegaly, and stigmata of bleeding/bruising.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Performance status
         </strong>
         (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count (CBC) with differential count
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum chemistries, including electrolytes, glucose, renal function tests, liver function tests
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatitis B serology
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical tests
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electrocardiogram (EKG)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chest radiograph
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           BCR-ABL1
          </em>
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         Quantitative reverse transcription polymerase chain reaction (qPCR) for
         <em>
          BCR-ABL1
         </em>
         in blood or bone marrow, to establish a baseline for subsequent response monitoring.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow morphology
         </strong>
         , including percentage of blasts, promyelocytes, and basophils.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Diagnostic criteria for distinguishing AP CML from CP CML and BP CML are described below. (See
         <a class="local">
          'Diagnosis of AP CML'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Karyotype
         </strong>
         – Giemsa-stained chromosome banding analysis (CBA) to confirm the presence of t(9;22) (q34;q11)/Philadelphia chromosome (Ph)
         <strong>
          and
         </strong>
         identify additional chromosomal abnormalities (ACA) in Ph+ cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fluorescence in situ hybridization (FISH) is not an adequate substitute for CBA, because it will not detect ACAs, but FISH should be performed if Ph is not detected by CBA.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2312521475">
         <span class="h2">
          Mutation testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          BCR-ABL1
         </em>
         kinase domain mutations inform the choice of TKI, as described below. (See
         <a class="local">
          'Mutation-guided'
         </a>
         below.)
        </p>
        <p>
         Mutation analysis is required for patients with transformed AP CML (ie, AP CML that arose during TKI treatment for CP CML), but it is not required for patients who initially presented with AP CML (ie, de novo AP CML).
        </p>
        <p class="headingAnchor" id="H3754294875">
         <span class="h2">
          Hematopoietic cell transplantation evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who may require allogeneic hematopoietic cell transplantation (HCT), it is important to determine eligibility and initiate a donor search. (See
         <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">
          "Determining eligibility for allogeneic hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         The timing for this evaluation is influenced by whether the patient has de novo AP CML versus transformed AP CML. All patients with transformed AP CML, except those who are frail, should be referred promptly; for patients with de novo AP CML, many experts await the response to initial therapy before referring the patient for evaluation. (See
         <a class="local">
          'de novo versus transformed AP'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H419379642">
         <span class="h1">
          DIAGNOSIS OF AP CML
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation, diagnosis, and differential diagnosis of CML are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p>
         We favor use of the World Health Organization (WHO) criteria to diagnose AP CML  (
         <a class="graphic graphic_table graphicRef60902" href="/z/d/graphic/60902.html" rel="external">
          table 2
         </a>
         ). The WHO model defines AP CML as 10 to 19 percent blasts in blood or bone marrow, which distinguishes AP CML from chronic phase (CP) CML (&lt;10 percent blasts) and blast phase (BP; ≥20 percent blasts). These criteria are consistent with contemporary criteria for the diagnosis of acute myeloid leukemia (AML) and it reflects the important prognostic role of the blast count in CML [
         <a href="#rid1">
          1,2
         </a>
         ]. By contrast, the European LeukemiaNet (ELN) [
         <a href="#rid3">
          3
         </a>
         ] and MD Anderson Cancer Center (MDACC) [
         <a href="#rid4">
          4
         </a>
         ] models use 30 percent blasts and/or promyelocytes to distinguish AP CML from CP CML; other differences between diagnostic models are presented below. It should be noted that, historically, most clinical studies used a threshold of 30 percent blasts to define BP CML.
        </p>
        <p>
         In addition to establishing the diagnosis of AP CML, it is important to distinguish between de novo AP CML and transformed AP CML, as described below. (See
         <a class="local">
          'de novo versus transformed AP'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1558207436">
         <span class="h2">
          World Health Organization
         </span>
         <span class="headingEndMark">
          —
         </span>
         World Health Organization (WHO) criteria diagnose AP CML based on the presence of any of the following [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blasts
         </strong>
         – 10 to 19 percent blasts in blood or bone marrow.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basophils
         </strong>
         – ≥20 percent basophils in blood.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombocytopenia
         </strong>
         – Platelets persistently &lt;100,000/microL (&lt;100 x 10
         <sup>
          9
         </sup>
         /L) unrelated to therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional chromosomal abnormalities (ACA)
         </strong>
         – Major route ACAs in Philadelphia chromosome-positive (Ph+) cells detected at diagnosis (eg, second Ph chromosome, trisomy 8, isochromosome 17q, trisomy 19), complex karyotype, or abnormalities of 3q26.2. Other chromosomal findings in Ph+ cells are considered minor route ACAs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          New ACA while on treatment
         </strong>
         – Development of any new ACA (ie, major or minor route) in Ph+ cells while receiving treatment with a BCR-ABL1 tyrosine kinase inhibitor (TKI).
        </p>
        <p>
        </p>
        <p>
         According to WHO criteria, BP CML is diagnosed and distinguished from AP CML based on either infiltrative blasts in an extramedullary site or ≥20 percent blasts in blood or bone marrow [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1730260337">
         <span class="h2">
          Other models
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          European LeukemiaNet (ELN)
         </strong>
         – ELN diagnostic criteria for AP CML [
         <a href="#rid3">
          3
         </a>
         ] follow:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Blasts in blood or marrow 15 to 29 percent or blasts plus promyelocytes &gt;30 percent (with &lt;30 percent blasts)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Basophils ≥20 percent in blood
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Persistent thrombocytopenia &lt;100 x 10
         <sup>
          9
         </sup>
         /L, unrelated to therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Major route ACA (described above) in Ph+ cells that develops while receiving TKI treatment
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the ELN model, major route ACAs establish the diagnosis of AP CML only if they develop while on TKI treatment; by contrast, the WHO diagnoses AP CML if a major route ACA is present at the time of initial diagnosis or if any ACA develops while on treatment [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MDACC (MD Anderson Cancer Center)
         </strong>
         – The MDACC model diagnoses AP CML as follows [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Blasts in blood or marrow 15 to 29 percent; blasts plus promyelocytes &gt;30 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Basophils ≥20 percent in blood
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Persistent thrombocytopenia &lt;100 x 10
         <sup>
          9
         </sup>
         /L, unrelated to therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ACA (either major route ACA or other) in Ph+ cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sokal
         </strong>
         – We consider the Sokal model to be less helpful, because it is primarily based on clinical findings (eg, progressive splenomegaly, anemia unrelated to therapy, marrow fibrosis, unexplained fever) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1264492957">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p>
         Our approach to management of CML is consistent with recommendations of the European LeukemiaNet [
         <a href="#rid6">
          6
         </a>
         ] and the US National Comprehensive Cancer Network [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7498005">
         <span class="h2">
          de novo versus transformed AP
         </span>
         <span class="headingEndMark">
          —
         </span>
         We distinguish between accelerated phase (AP) CML that presents
         <strong>
          de novo
         </strong>
         versus AP CML that has
         <strong>
          transformed
         </strong>
         from prior chronic phase (CP) CML, because this influences management and prognosis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          de novo
         </strong>
         <strong>
          CML AP
         </strong>
         refers to a patient who presents with AP CML. Patients with de novo AP CML have not previously been treated with a tyrosine kinase inhibitor (TKI; ie, treatment-naïve), because this is the first presentation of the disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of de novo AP CML is described below. (See
         <a class="local">
          'Treatment of de novo AP CML'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transformed
         </strong>
         <strong>
          CML AP
         </strong>
         refers to a patient whose AP CML arose while being treated with a TKI for CP CML; disease progression may be due to TKI-resistance from a
         <em>
          BCR-ABL1
         </em>
         mutation. Transformed AP CML generally has a less favorable prognosis than de novo AP CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with transformed AP CML, it is important to consider adherence with the prior TKI regimen, as poor adherence is a possible cause of disease progression. It is important to ask about adherence to the TKI dose and schedule and use of other medications or herbal supplements that may impair the metabolism of the TKI.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of transformed AP CML is described below. (See
         <a class="local">
          'Treatment of transformed AP CML'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H779217564">
         <span class="h2">
          Treatment of de novo AP CML
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who present with
         <strong>
          de novo
         </strong>
         <strong>
          AP CML
         </strong>
         , we suggest initial treatment with a second-generation (2G) TKI, rather than allogeneic hematopoietic cell transplantation (HCT) or treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         . Compared with the favorable balance of benefits and toxicity of a 2G TKI, for patients with de novo AP CML, the adverse effects and possible treatment-related mortality (TRM) of allogeneic HCT outweigh the potential for disease control and cure. Compared with ponatinib, 2G TKIs have comparable efficacy (except for patients with
         <em>
          BCR-ABL1
         </em>
         T315I mutation), but less toxicity; compared with imatinib, 2G TKIs achieve faster and deeper responses, yet have comparable toxicity  (
         <a class="graphic graphic_algorithm graphicRef131960" href="/z/d/graphic/131960.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid8">
          8-11
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selection of a TKI
         </strong>
         – The choice of a 2G TKI is based on the patient's comorbid conditions and characteristic adverse effects (AEs)  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 3
         </a>
         ). AEs of 2G TKIs are generally modest, but vary with the individual agent. (See
         <a class="local">
          '2G tyrosine kinase inhibitors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We do not routinely perform mutation testing for patients with de novo AP CML, but some experts favor mutation testing in this setting. If a
         <em>
          BCR-ABL1
         </em>
         T315I mutation was detected, we treat with
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         (the only TKI that is effective for this mutation) (see
         <a class="local">
          'Ponatinib'
         </a>
         below). Alternative management for a patient with T315I and significant cardiovascular conditions are discussed below. (See
         <a class="local">
          'Other treatments'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – There are no prospective data comparing indefinite continuation of a TKI versus allogeneic HCT in patients who achieved a complete cytogenetic response (CCyR) with initial TKI treatment. A single center study reported that treatment with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         was associated with 90 percent CCyR among 21 patients with de novo AP CML [
         <a href="#rid12">
          12
         </a>
         ]. In studies that included both de novo and transformed AP CML, treatment with a 2G TKI was associated with two- to four-year overall survival (OS) in approximately two-thirds of patients [
         <a href="#rid13">
          13-15
         </a>
         ]; however, outcomes with de novo AP CML are probably more favorable than outcomes of the mixed populations of patients (ie, de novo and transformed AP CML) in these studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We continue TKI treatment indefinitely. We currently suggest
         <strong>
          not
         </strong>
         pursuing TKI discontinuation for patients with AP CML who have a robust and prolonged molecular response, as there are no currently-available data to support this approach.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2336016676">
         <span class="h2">
          Treatment of transformed AP CML
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment for
         <strong>
          transformed AP CML
         </strong>
         is guided by the patient's suitability for allogeneic HCT  (
         <a class="graphic graphic_algorithm graphicRef131961" href="/z/d/graphic/131961.html" rel="external">
          algorithm 2
         </a>
         ), which depends on age, medical fitness, and an appropriate donor, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4494.html" rel="external">
          "Hematopoietic cell transplantation in chronic myeloid leukemia", section on 'Eligibility'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2169204270">
         <span class="h3">
          Transplant-eligible
         </span>
         <span class="headingEndMark">
          —
         </span>
         For transplant-eligible patients with transformed AP CML, we generally suggest allogeneic HCT rather than treatment with a TKI alone, although treatment choices must be individualized. For transformed AP CML, long-term disease control and possible cure with allogeneic HCT generally outweigh the adverse effects and risk of TRM; by contrast, 2G TKIs or
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         have less potential for long-term disease control. Nevertheless, transplantation has not been shown to yield superior survival and some patients who have an excellent response to a TKI may choose to continue the TKI alone, because they place greater weight on avoidance of transplant-related toxicity than on potential benefits of allogeneic HCT.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior to transplantation
         </strong>
         – During the search for a transplant donor, the patient with transformed AP CML should be treated according to the presence of a
         <em>
          BCR-ABL1
         </em>
         kinase domain mutation, comorbid conditions, and characteristic AEs  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 3
         </a>
         ). Mutation testing is particularly important for transformed AP CML because disease progression usually reflects resistance to the prior TKI. (See
         <a class="local">
          'Tyrosine kinase inhibitor selection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally proceed to allogeneic HCT as soon as the disease can be brought under control with a TKI. Treatment with a TKI does not compromise transplant outcomes or increase transplant-related toxicity [
         <a href="#rid16">
          16-22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – Outcomes with allogeneic HCT for AP CML vary because of different eligibility criteria and small numbers of patients in most studies. A retrospective analysis of registry data that included 168 patients with AP CML reported no difference in OS between allogeneic HCT and treatment with a TKI alone; however, the conclusions were limited by varying definitions of AP, inclusion of both de novo and transformed AP CML, and unbalanced numbers of patients in the cohorts [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A multicenter study of transplantation in 28 patients with advanced phase CML (ie, both AP CML and BP CML) reported 59 percent three-year OS [
         <a href="#rid24">
          24
         </a>
         ]. A single-center study reported 45 percent long-term survival after allogeneic HCT for 40 patients with advanced phase CML [
         <a href="#rid25">
          25
         </a>
         ]. A registry study reported 37 percent five-year OS among 14 patients with advanced phase CML; non-relapse mortality was 12 percent, but this included patients with AP CML and CP CML [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Donor selection, graft source, conditioning regimen, prophylaxis for graft-versus-host disease (GVHD), and further details of outcomes with allogeneic HCT for CML are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4494.html" rel="external">
          "Hematopoietic cell transplantation in chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2204898393">
         <span class="h3">
          Not transplant-eligible
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with transformed AP CML who are
         <strong>
          not
         </strong>
         suitable for allogeneic HCT (eg, not medically-fit, no suitable donor, or the patient declines), we select a TKI according to
         <em>
          BCR-ABL1
         </em>
         mutation analysis, comorbid conditions, and toxicity profile, as described below. (See
         <a class="local">
          'Tyrosine kinase inhibitor selection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1378125641">
         <span class="h1">
          TYROSINE KINASE INHIBITOR SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following should be considered when selecting a BCR-ABL1 tyrosine kinase inhibitor (TKI) for treatment of accelerated phase (AP) CML:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mutation status
         </strong>
         –
         <em>
          BCR-ABL1
         </em>
         kinase domain mutation testing should be performed for all patients with transformed AP CML. We do not routinely perform mutation testing in patients who present with de novo AP CML. Selection of a TKI based on mutation status is discussed below. (See
         <a class="local">
          'Mutation-guided'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TKI adverse effects (AEs)
         </strong>
         – Each TKI is associated with characteristic AEs  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 3
         </a>
         ). Selection of a TKI based on AEs is discussed below. (See
         <a class="local">
          'Toxicity-guided'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comorbid conditions
         </strong>
         – A history of heart disease, lung conditions, diabetes, pancreatitis, and other comorbid illnesses should be considered in choosing a TKI. (See
         <a class="local">
          'Toxicity-guided'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3720306614">
         <span class="h2">
          Mutation-guided
         </span>
         <span class="headingEndMark">
          —
         </span>
         Detection of certain
         <em>
          BCR-ABL1
         </em>
         kinase domain mutations contraindicates particular TKIs:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bosutinib
         </strong>
         – Avoid
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         for T315I, V299L, G250E, or F317L mutation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dasatinib
         </strong>
         – Avoid
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         for T315I/A, F317L/V/I/C, or V299L mutation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nilotinib
         </strong>
         – Avoid
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         for T315I, Y253H, E255K/V, F359V/C/I, or G250E mutation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ponatinib
         </strong>
         – None known.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imatinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         is ineffective for numerous
         <em>
          BCR-ABL1
         </em>
         mutations and is generally avoided for treatment of AP CML.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4260692286">
         <span class="h2">
          Comorbidity-guided
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain comorbid conditions influence the choice of a TKI:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heart disease
         </strong>
         – We favor
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         (and avoid
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ) for patients with arrhythmias, coronary artery disease, or hyperglycemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes mellitus
         </strong>
         – We favor
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         (and avoid
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ) for patients with arrhythmias, coronary artery disease, or hyperglycemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pancreatitis
         </strong>
         – We favor
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         (and avoid
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ) for patients with pancreatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung diseases
         </strong>
         – We favor
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         or
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         (and avoid
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ) for patients who have lung disease or are at risk for pleural effusion.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1461151863">
         <span class="h2">
          Toxicity-guided
         </span>
         <span class="headingEndMark">
          —
         </span>
         We consider the following to be defining toxicities of second-generation (2G) TKIs:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dasatinib
         </strong>
         – Pleural effusion, pulmonary hypertension, prolonged QTc interval, platelet dysfunction
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nilotinib
         </strong>
         – Coronary, cerebral, and peripheral vascular disease; prolonged QTc interval; hyperglycemia; pancreatitis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bosutinib
         </strong>
         – Diarrhea, abnormal liver function, rash, pancreatitis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3068897990">
         <span class="h2">
          2G tyrosine kinase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Each 2G tyrosine kinase inhibitor (TKI) is associated with characteristic AEs, some of which may not be manifest for months or years.
        </p>
        <p>
         In addition, all TKIs are associated with certain common AEs (eg, cytopenias, rash, nausea, muscle cramps, edema, diarrhea, fatigue) early in treatment, but most of the early AEs are modest and self-limited. Management of early AEs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Managing toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1040869966">
         <span class="h3">
          Dasatinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          Dasatinib
         </a>
         should be avoided in patients with lung disease or who at risk for pleural effusion. Treatment with dasatinib is associated with cytopenias, pleural effusion/fluid retention, QT prolongation, and bleeding  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – For AP CML,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         should be taken 140 mg once daily, with or without a meal; note that the recommended dose for AP CML differs from that in chronic phase (CP) CML [
         <a href="#rid27">
          27
         </a>
         ]. Patients should be screened by electrocardiogram (EKG) for QTc interval at baseline, and hypokalemia or hypomagnesemia should be corrected before dasatinib administration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Caution is advised in patients who require anticoagulants, drugs that inhibit platelet function, anti-arrhythmic agents, and medications or supplements that may prolong QTc  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 4
         </a>
         ), as described separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Dasatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Most AEs are mild, but patients may experience QTc prolongation, fluid retention (grade ≥3 in 4 percent), exacerbation of heart failure, pleural effusions, or bleeding from platelet dysfunction  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid27">
          27
         </a>
         ]. Severe central nervous system (CNS) and gastrointestinal hemorrhages have been reported in approximately 1 and 4 percent of patients, respectively; most cases were associated with severe thrombocytopenia, anticoagulants, and/or inhibitors of platelet function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – In a trial that randomly assigned 317 patients with AP CML to
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         140 mg once daily versus dasatinib 70 mg twice daily, response rates were comparable in both arms, but there was less toxicity with the single daily dose (ie, 20 versus 39 percent pleural effusions); most patients probably had transformed AP CML, because resistance or intolerance to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         was a study entry criterion [
         <a href="#rid13">
          13
         </a>
         ]. With median follow-up of 15 months, rates of complete hematologic response (CHR), major cytogenetic response, and complete cytogenetic response (CCyR) were 50, 41, and 32 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         (70 mg twice daily) in 174 patients with AP CML (resistant or intolerant to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ) was associated with 64 percent major hematologic response (MHR), 45 percent CHR, and 32 percent CCyR after 14 month follow-up [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The US Food and Drug Administration (FDA) and European Medical Agency (EMA) labels recommend
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         140 mg daily for AP CML [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4168336858">
         <span class="h3">
          Nilotinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          Nilotinib
         </a>
         should be avoided in patients with heart disease or diabetes mellitus; it is the only TKI that must be taken twice daily and without food. Nilotinib is associated with cytopenias, hepatotoxicity, QTc prolongation, pancreatitis, and long-term cardiovascular complications  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          Nilotinib
         </a>
         400 mg should be taken twice daily with water (approximately 12 hours apart); patients should avoid food ≥2 hours before and ≥1 hour after each dose. Note that the recommended dose for AP CML differs from that for CP CML [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prior to initiating
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         treatment, serum lipase and amylase should be tested, baseline QTc interval measured, potassium and magnesium levels corrected, and other medications that may prolong QTc should be avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Treatment with
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         has been associated with reversible and usually asymptomatic elevations in unconjugated bilirubin, lipase, and amylase. Most AEs are mild and self-limited, but pancreatitis and a low incidence of sudden deaths (possibly due to dysrhythmias) have been reported. Later effects include occlusive cardiac, cerebral, and peripheral artery disease; liver disease; and hyperglycemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – Treatment of 119 patients with AP CML with
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         (400 mg twice daily; escalated to 600 mg twice daily for inadequate response) was associated with 79 percent one-year overall survival (OS), 47 percent hematologic response (26 percent CHR), and 29 percent major cytogenetic response (MCyR; 16 percent CCyR) [
         <a href="#rid31">
          31
         </a>
         ]. Grade ≥3 AEs included thrombocytopenia (35 percent), neutropenia (21 percent), and increased lipase (18 percent). With longer follow-up, 66 percent of patients who achieved MCyR sustained that response at 24 months [
         <a href="#rid14">
          14
         </a>
         ]. Another study of 46 patients with imatinib-resistant AP CML reported similar rates of hematologic and cytogenetic response (33 and 22 percent, respectively) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The US FDA [
         <a href="#rid30">
          30
         </a>
         ] and EMA labels recommend
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         400 mg twice daily for AP CML.
        </p>
        <p class="headingAnchor" id="H1056973523">
         <span class="h3">
          Bosutinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          Bosutinib
         </a>
         should be avoided in patients with liver or kidney dysfunction, diarrhea, and heart failure. Treatment is associated with cytopenias, diarrhea, abnormal liver function, and fluid retention.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          Bosutinib
         </a>
         500 mg once daily; note that the recommended dose for AP CML differs from that in CP CML [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Treatment is associated with diarrhea, nausea, and abdominal pain; the most common grade ≥3 AEs are diarrhea and abnormal liver function tests; there is a low incidence of cardiac and vascular AEs with
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         treatment with ≥4 year follow-up [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – Treatment of 72 patients with AP CML was associated with 57 percent overall hematologic response (31 percent CHR) by week 48; transformation to blast phase was reported in three patients [
         <a href="#rid33">
          33
         </a>
         ]. In another report, 57 percent of 14 patients with AP CML attained or maintained baseline overall hematologic response and 40 percent attained or maintained MCyR [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The US FDA [
         <a href="#rid33">
          33
         </a>
         ] and EMA recommend
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         500 mg once daily for AP CML.
        </p>
        <p class="headingAnchor" id="H4117000293">
         <span class="h2">
          Ponatinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         , the only third-generation TKI, is associated with significant cardiovascular (CV) risks and complications, but it is the only TKI that is effective against the
         <em>
          BCR-ABL1
         </em>
         T315I kinase domain mutation. For patients with the T315I mutation who have substantial CV risk factors, other treatments may be preferred. (See
         <a class="local">
          'Other treatments'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         45 mg should be taken once daily, with or without food. We do not reduce the ponatinib dose in patients with AP CML because it is uncertain if this will compromise response and/or reduce AEs in patients with AP CML. However, some experts reduce ponatinib to 30 mg for AP CML for BCR-ABL1 &lt;1 percent [
         <a href="#rid35">
          35
         </a>
         ]. Many clinicians co-administer
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         to mitigate CV complications of ponatinib, but this has not been shown to be beneficial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Treatment with
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         is associated with CV AEs in more than one-fifth of patients, arterial thrombosis in 8 percent, and liver toxicity/failure is possible [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – A phase 2 study (PACE) reported outcomes with
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         in 83 patients with AP CML (resistant or intolerant to
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ), including patients with
         <em>
          BCR-ABL1
         </em>
         T315I mutations [
         <a href="#rid38">
          38
         </a>
         ]. At five years, progression-free survival and OS were 22 and 49 percent, respectively. Other outcomes included MHR (61 percent), MCyR (49 percent), CCyR (31 percent), and major molecular response (MMR; 22 percent). In the PACE study, grade ≥3 thrombocytopenia, neutropenia, and anemia occurred in 44, 37, and 22 percent, respectively. The most common non-hematological toxicities were abdominal pain (42 percent), rash (38 percent), constipation (29 percent), dry skin (32 percent), and fatigue (38 percent) [
         <a href="#rid38">
          38
         </a>
         ]. CV, cerebrovascular, and peripheral vascular events occurred in 7, 4, and 5 percent, respectively; most of these patients had at least one other risk factor (eg, hypertension, diabetes, hypercholesterolemia, obesity). Of the patients who continued ponatinib after a vascular event, 36 percent had subsequent events. Overall, severe AEs led to the discontinuation of therapy in 11 percent of patients; two patients died, including one death that was thought to be related to ponatinib (fungal pneumonia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another study,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         treatment of 83 patients with AP CML was associated with 52 percent MHR (47 percent CHR) [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         is approved for treatment of AP CML in which no other TKIs are indicated and for patients with
         <em>
          BCR-ABL1
         </em>
         T315I mutation by the US FDA [
         <a href="#rid36">
          36
         </a>
         ] and the EMA.
        </p>
        <p class="headingAnchor" id="H2875568694">
         <span class="h1">
          OTHER TREATMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other treatments, alone or in combination with a tyrosine kinase inhibitor (TKI), are under investigation. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asciminib
         </strong>
         –
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          Asciminib
         </a>
         is an allosteric inhibitor of BCR-ABL1 that specifically targets the ABL myristoyl pocket (STAMP). Asciminib is approved by the US Food and Drug Administration (FDA) for chronic phase (CP) CML that is resistant to ≥2 TKIs, including patients who harbor the
         <em>
          BCR-ABL1
         </em>
         T315I mutation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The multicenter phase 3 ASCEMBL trial reported that
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         had superior efficacy compared with
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         in patients with CP CML who had previously received ≥2 TKIs [
         <a href="#rid39">
          39
         </a>
         ]. Patients were randomly assigned (2:1) to receive asciminib 40 mg twice daily versus bosutinib 500 mg once daily. Major molecular response (MMR) rate at week 24 was 26 percent with asciminib compared with 13 percent with bosutinib. Asciminib was also associated with fewer grade ≥3 adverse events (AE; 51 versus 61 percent, respectively) and fewer AEs leading to treatment discontinuation (6 versus 21 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment with
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         in eight patients with AP CML reported complete hematologic response (CHR) in seven of eight patients and complete cytogenetic response (CCyR) and MMR in one of six patients [
         <a href="#rid40">
          40
         </a>
         ]. Asciminib was active in patients who had resistance to or unacceptable AEs from TKIs, including patients with a T315I mutation in whom
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         had failed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another study, treatment with
         <a class="drug drug_general" data-topicid="134240" href="/z/d/drug information/134240.html" rel="external">
          asciminib
         </a>
         was associated with complete hematologic response (CHR) in seven of eight patients with accelerated phase (AP) CML and complete cytogenetic response (CCyR) and major molecular response (MMR) in one of six patients; asciminib was active in patients who had resistance to or unacceptable adverse effects (AEs) from TKIs, including patients with a T315I mutation in whom
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         had failed [
         <a href="#rid40">
          40
         </a>
         ]. AEs were primarily asymptomatic elevations in lipase or amylase and grade &lt;3 rash, fatigue, nausea, headache, or and arthralgias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Omacetaxine
         </strong>
         <strong>
          mepesuccinate
         </strong>
         (previously known as homoharringtonine) is an inhibitor of protein synthesis that is approved by the US FDA for treatment of AP CML in adults with resistance or intolerance to ≥2 TKIs [
         <a href="#rid41">
          41
         </a>
         ]. Its use is generally limited to patients with the
         <em>
          BCR-ABL1
         </em>
         T315I mutation who have severe cardiovascular complications or risk factors that contraindicate treatment with
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         and are ineligible for allogeneic hematopoietic cell transplantation (HCT).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The recommended dose is 1.25 mg/m
         <sup>
          2
         </sup>
         subcutaneous injection twice daily for 14 days of a 28-day cycle for the induction phase and 1.25 mg/m
         <sup>
          2
         </sup>
         subcutaneous injection twice daily for 7 days of a 28-day cycle for maintenance [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment of 41 patients with AP CML resistant to an initial TKI reported 11 percent CHR and one additional patient with &lt;5 percent blasts in bone marrow [
         <a href="#rid42">
          42
         </a>
         ]. Median time to response was two months and median duration of response was five months. Common toxicities included thrombocytopenia, neutropenia, anemia, infection, diarrhea, nausea, pyrexia, fatigue, asthenia, and arthralgia. The use of
         <a class="drug drug_general" data-topicid="87038" href="/z/d/drug information/87038.html" rel="external">
          omacetaxine
         </a>
         in patients with chronic phase disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy", section on 'Omacetaxine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interferon
         </strong>
         – Pegylated interferon is being studied in combination with 2G TKIs [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         –
         <a class="drug drug_general" data-topicid="8797" href="/z/d/drug information/8797.html" rel="external">
          Azacitidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8855" href="/z/d/drug information/8855.html" rel="external">
          decitabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         , immunotherapies (eg, immune checkpoint blockade, leukemia-associated antigens, BCR-ABL1 peptides, dendritic cell vaccines) and targeted agents (eg, aurora kinase inhibitors, farnesyl transferase inhibitors, JAK2 inhibitors) are being studied to deepen the molecular response to TKIs [
         <a href="#rid44">
          44-50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1808894643">
         <span class="h1">
          RESPONSE MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Response to a tyrosine kinase inhibitor (TKI) is evaluated by the timely achievement of hematologic, cytogenetic, and molecular milestones  (
         <a class="graphic graphic_table graphicRef90418" href="/z/d/graphic/90418.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. Response is assessed by serial measurement in peripheral blood of
         <em>
          BCR-ABL1
         </em>
         by quantitative reverse transcriptase polymerase chain reaction (qPCR). The qPCR assay should be standardized and have a sensitivity of ≥4.5-log reduction from the baseline.
        </p>
        <p>
         Optimal responses are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         3 months:
         <em>
          BCR-ABL1
         </em>
         (International Scale [IS]) ≤10 percent and/or ≤35 percent Philadelphia chromosome-positive (Ph+) metaphase cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         6 months:
         <em>
          BCR-ABL1
         </em>
         IS ≤1 percent and/or 0 percent Ph+ cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         12 months:
         <em>
          BCR-ABL1
         </em>
         IS ≤0.1 percent
        </p>
        <p>
        </p>
        <p>
         After
         <em>
          BCR-ABL1
         </em>
         is ≤0.1 percent, it should be measured every three months for the first two years and then every three to six months thereafter. At very low levels, the level of transcripts can fluctuate several-fold with successive tests. However, if there is a 1-log increase in
         <em>
          BCR-ABL1
         </em>
         after achieving a 3-log molecular response (MR3), this should be confirmed by repeating qPCR in one to three months. Further details and definitions of hematologic, cytogenetic, and molecular milestones are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Response monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2434624749">
         <span class="h1">
          PROGNOSTIC FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Features that have been associated with outcomes in patients with accelerated phase (AP) CML include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          de novo versus transformed AP CML
         </strong>
         – The distinction between de novo and transformed AP CML has prognostic importance, but also guides the approach to initial treatment. (See
         <a class="local">
          'Treatment of de novo AP CML'
         </a>
         above and
         <a class="local">
          'Treatment of transformed AP CML'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Major route additional chromosomal abnormalities (ACA) versus minor route ACA
         </strong>
         – Major route ACAs (ie, second Philadelphia chromosome, trisomy 8, isochromosome 17q, trisomy 19) are associated with an adverse impact on survival [
         <a href="#rid51">
          51-53
         </a>
         ]. The impact of minor route ACAs is currently less well-defined.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased blasts
         </strong>
         – AP CML that was diagnosed because of increased blasts is associated with worse prognosis than AP CML that was diagnosed on the basis of other criteria (eg, basophils, ACAs) [
         <a href="#rid1">
          1,54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rate of response to treatment
         </strong>
         – Early response is predictive of long-term outcome. In a retrospective study, among 75 patients with AP CML, those who achieved
         <em>
          BCR-ABL1
         </em>
         &lt;10 percent at three months had better overall survival and event-free survival (both 95 percent) compared to those who did not (79 and 59 percent, respectively) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular abnormalities
         </strong>
         – Mutations of certain genes are found with high frequency in AP CML, but their prognostic importance is presently uncertain. As examples, single nucleotide variations (SNVs) and small insertions or deletions (indels) in
         <em>
          RUNX1
         </em>
         and
         <em>
          ASXL1
         </em>
         , plus
         <em>
          IKZF1
         </em>
         exon deletions; mutations of epigenetic regulators; and gene fusions involving
         <em>
          RUNX1
         </em>
         ,
         <em>
          MLL
         </em>
         (
         <em>
          KMT2A
         </em>
         ), and
         <em>
          CBFB
         </em>
         are common in AP CML [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1892150213">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117207.html" rel="external">
          "Society guideline links: Chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/684.html" rel="external">
          "Patient education: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic myeloid leukemia (CML)
         </strong>
         is associated with t(9;22)(q34;q11), the Philadelphia chromosome (Ph), which creates the
         <em>
          BCR-ABL1
         </em>
         fusion gene and a constitutively active tyrosine kinase that is sensitive to treatment with a BCR-ABL1 tyrosine kinase inhibitor (TKI). Up to 90 percent of patients with CML present in chronic phase (CP) CML, which is a relatively indolent disorder that responds well to TKIs; the remainder present with either accelerated phase (AP) CML or blast phase (BP; also called blast crisis) CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis of AP CML
         </strong>
         – We favor use of the World Health Organization (WHO) criteria to distinguish AP CML from CP CML and BP CML (see
         <a class="local">
          'World Health Organization'
         </a>
         above). WHO criteria for AP CML requires at least one of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Blasts
         </strong>
         – 10 to 19 percent myeloblasts in blood or bone marrow
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Basophils
         </strong>
         – ≥20 percent in blood
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Thrombocytopenia
         </strong>
         – Platelets persistently &lt;100 x 10
         <sup>
          9
         </sup>
         /L (unrelated to therapy)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Additional chromosomal abnormalities (ACA)
         </strong>
         – Major route ACAs in Ph+ cells at diagnosis (eg, second Ph chromosome, trisomy 8, isochromosome 17q, trisomy 9), complex karyotype, or abnormalities of 3q26.2
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          New ACA while on treatment
         </strong>
         – Development of any new ACA (ie, major route ACA or others) in Ph+ cells while treated with a TKI
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other models apply different diagnostic criteria, but we favor the WHO model because it is aligned with diagnostic criteria for other hematologic malignancies. (See
         <a class="local">
          'Other models'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distinguishing de novo AP CML from transformed AP CML
         </strong>
         has important implications for treatment and prognosis. (See
         <a class="local">
          'de novo versus transformed AP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          de novo
         </strong>
         <strong>
          AP
         </strong>
         <strong>
          CML
         </strong>
         refers to a patient whose initial presentation with CML is accelerated phase. Patients with de novo AP CML have not previously been treated with a TKI (ie, treatment-naïve), because this is the first presentation of their disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transformed
         </strong>
         <strong>
          AP
         </strong>
         <strong>
          CML
         </strong>
         refers to a patient who previously presented with CP CML, but the disease progressed to AP (ie, transformed) during treatment with a TKI. Disease progression may be due to TKI-resistance from a
         <em>
          BCR-ABL1
         </em>
         mutation. Transformed AP CML generally has a less favorable prognosis than de novo AP CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of de novo AP CML
         </strong>
         – For patients with de novo AP CML, we suggest treatment with a second-generation (2G) TKI, rather than allogeneic hematopoietic cell transplantation (HCT) or treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         )  (
         <a class="graphic graphic_algorithm graphicRef131960" href="/z/d/graphic/131960.html" rel="external">
          algorithm 1
         </a>
         ) because, compared with the other approaches, a 2G TKI provides the most favorable balance of efficacy and toxicity. (See
         <a class="local">
          'Treatment of de novo AP CML'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Selection of a 2G TKI for treatment of de novo AP CML is informed by comorbid conditions, toxicity profile, and
         <em>
          BCR-ABL1
         </em>
         mutation (if tested), as described above. (See
         <a class="local">
          'Tyrosine kinase inhibitor selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment for
         </strong>
         <strong>
          transformed AP CML
         </strong>
         is guided by the patient's suitability for allogeneic HCT  (
         <a class="graphic graphic_algorithm graphicRef131961" href="/z/d/graphic/131961.html" rel="external">
          algorithm 2
         </a>
         ). Eligibility for transplantation depends on age, medical fitness, and an available suitable donor, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4494.html" rel="external">
          "Hematopoietic cell transplantation in chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transplant-eligible
         </strong>
         – For transplant-eligible patients with transformed AP CML, we generally suggest allogeneic HCT rather than treatment with a TKI alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), although we recognize that treatment must be individualized. Long-term disease control and possible cure with allogeneic HCT generally outweigh the adverse effects and risk of transplant-related mortality (TRM); by contrast, 2G TKIs or
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         have less potential for long-term disease control of transformed AP CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Not transplant-eligible
         </strong>
         – For patients with transformed AP CML who are not suitable for allogeneic HCT (eg, not medically-fit, no suitable donor, or the patient declines), we select a TKI according to
         <em>
          BCR-ABL1
         </em>
         mutation analysis, comorbid conditions, and toxicity profile. (See
         <a class="local">
          'Not transplant-eligible'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selection of a TKI
         </strong>
         – We select a TKI based on the following considerations (see
         <a class="local">
          'Tyrosine kinase inhibitor selection'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mutation status
         </strong>
         – For patients with transformed AP CML, we suggest
         <em>
          BCR-ABL1
         </em>
         mutation-guided TKI selection (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, we generally do not perform mutation analysis for patients with de novo AP CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Selection of a TKI based on
         <em>
          BCR-ABL1
         </em>
         mutations is presented above. (See
         <a class="local">
          'Mutation-guided'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Comorbid conditions
         </strong>
         – Diabetes or disease of the heart, lung, liver, or pancreas may influence the choice of TKI, as described above. (See
         <a class="local">
          'Comorbidity-guided'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Toxicity profile
         </strong>
         – Each TKI is associated with characteristic adverse effects (AEs) and selection may be influenced by toxicity profile. (See
         <a class="local">
          'Toxicity-guided'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response monitoring
         </strong>
         – Response to a TKI is evaluated by the timely achievement of hematologic, cytogenetic, and molecular milestones  (
         <a class="graphic graphic_table graphicRef90418" href="/z/d/graphic/90418.html" rel="external">
          table 5
         </a>
         ), as described above. (See
         <a class="local">
          'Response monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lauseker M, Bachl K, Turkina A, et al. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Am J Hematol 2019; 94:1236.
          </a>
         </li>
         <li class="breakAll">
          WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988; 25:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deininger MW, Shah NP, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurion R, Gafter-Gvili A, Vidal L, et al. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica 2013; 98:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohanian M, Kantarjian HM, Quintas-Cardama A, et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk 2014; 14:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009; 113:6322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012; 26:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 2015; 90:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109:1782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour E, Cortes J, Kantarjian H, et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007; 110:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimoni A, Leiba M, Schleuning M, et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia 2009; 23:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breccia M, Palandri F, Iori AP, et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res 2010; 34:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SE, Choi SY, Kim SH, et al. Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Hematology 2014; 19:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piekarska A, Gil L, Prejzner W, et al. Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome. Ann Hematol 2015; 94:1891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu B, Lin X, Lee HC, et al. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma 2020; 61:2811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115:1880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boehm A, Walcherberger B, Sperr WR, et al. Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience. Biol Blood Marrow Transplant 2011; 17:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lübking A, Dreimane A, Sandin F, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplant 2019; 54:1764.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf (Accessed on June 01, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 2009; 27:3472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109:4143.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s026lbl.pdf (Accessed on June 01, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111:1834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/20334s007s008lbl.pdf (Accessed on June 01, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kantarjian HM, Mauro MJ, et al. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol 2021; 106:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 2021; 138:2042.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf (Accessed on June 01, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan O, Talati C, Isenalumhe L, et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv 2020; 4:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 2021; 138:2031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med 2019; 381:2315.
          </a>
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf?et_cid=30334780&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203585lbl.pdf (Accessed on October 26, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kantarjian HM, Rea D, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer 2015; 121:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westerweel PE, Te Boekhorst PAW, Levin MD, Cornelissen JJ. New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia. Front Oncol 2019; 9:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruggiu M, Oberkampf F, Ghez D, et al. Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. Leuk Lymphoma 2018; 59:1659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abaza Y, Kantarjian H, Alwash Y, et al. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol 2020; 95:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maiti A, Franquiz MJ, Ravandi F, et al. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol 2020; 143:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes J, Jabbour E, Daley GQ, et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007; 110:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes J, Quintás-Cardama A, Garcia-Manero G, et al. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 2007; 110:2000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borthakur G, Dombret H, Schafhausen P, et al. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica 2015; 100:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massimino M, Stella S, Tirrò E, et al. Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia. Mol Cancer 2018; 17:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 2016; 127:2742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118:6760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hehlmann R, Voskanyan A, Lauseker M, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 2020; 34:2074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma D, Kantarjian H, Shan J, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010; 116:2673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohanian M, Kantarjian HM, Shoukier M, et al. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol 2020; 95:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Branford S, Kim DDH, Apperley JF, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia 2019; 33:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ochi Y, Yoshida K, Huang YJ, et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun 2021; 12:2833.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4514 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31456269" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31456269" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23803709" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3162181" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Characteristics of accelerated disease in chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3279515" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Staging and prognosis in chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32127639" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33022644" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20525995" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20525993" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22875617" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24311723" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24332214" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19369231" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22076466" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26040495" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16585011" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The effect of prior exposure to imatinib on transplant-related mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17062727" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17559140" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18596746" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19481800" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23684143" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26220759" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32662346" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19965667" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20601032" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30962502" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30962502" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487385" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264298" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264298" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18048643" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16775235" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16775235" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33638218" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34407543" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34407543" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32045474" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29567798" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34407542" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31826340" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31826340" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25586015" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31448223" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29179634" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32681739" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32289808" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17623836" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17849425" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25887498" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29455672" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27006386" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22039253" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32382082" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20499401" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32557828" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31209280" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33990592" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
